Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines

Summary

Uptake of radioiodinated mefa-iodobenzylguanidine (MIBG) has been demonstrated in the neural crest tumors, including neuroblastoma, pheochromocytoma, and carcinoid tumors, and is presently in use diagnostically and therapeutically in these settings. Cells comprising medulloblastoma, the most common central nervous system malignancy in childhood, may be derived from a common germinal neuroepithelial cell as neural crest tissue, and as a result, also may have the capacity for accumulating MIBG. To investigate this hypothesis, we measured thein vitro binding of [131I]MIBG to 9 medulloblastoma-derived cell lines and the SK-N-SH neuroblastoma line known to accumulate MIBG. Seven of the medulloblastoma lines exhibited MIBG binding. The cell line with the greatest uptake, D384 Med, bound 11.2 ± 0.9% of added [131I]MIBG activity compared with 47.1 ± 2.3% for the SK-N-SH cell line. When 2 of the cell lines, D384 Med and D458 Med, were treated with the a-particle emitting analogue meta-[211At]astatobenzylguanidine ([211At]MABG), as much as a 3-log cell kill was observed in limiting dilution clonogenic assays. Exposure to considerably higher activity levels of [211At]astatide was required to achieve a similar degree of cell kill, suggesting that this cytotoxicity was not related to nonspecific effects of α-particle irradiation. We conclude that the uptake capacity of medulloblastoma cell lines for [131I]MIBG uptakein vitro, while lower than that seen in SK-N-SH neuroblastoma cells, is sufficient to permit [211At]MABG to be used with significant therapeutic effectiveness.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Dehner LP: Peripheral and central primitive neuroectodermal tumors. Arch Pathol Lab Med 110: 997–1005, 1986

  2. 2.

    Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R: The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). Eur J Nucl Med 16: 325–335, 1990

  3. 3.

    Le Douarin N: The Neural Crest. Cambridge University Press, New York, 1982, pp 54–90

  4. 4.

    Friedman HS, Oakes WJ, Bigner SH, Wikstrand CJ, Bigner DD: Medulloblastoma: tumor biological and clinical perspectives. J Neurooncol 11: 1–15, 1991

  5. 5.

    Deutsch M, Reigel DH: Myelography and cytology in the treatment of medulloblastoma. Int J Radiat Oncol Phys 7: 721–725, 1981

  6. 6.

    Hall EJ: Radiobiology for the Radiologist. Lippincott, Philadelphia, 1988, pp 161–177

  7. 7.

    Strickland DK, Vaidyanathan G, Zalutsky MR: Cytotoxicity of α-particle emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res 54: 5414–5419, 1994

  8. 8.

    He X, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD: Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48: 48–68, 1989

  9. 9.

    He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, Trojanowski JQ, Bigner DD: Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med and D458 Med) and their transplantable xenografts. Lab Invest 64: 833–843, 1991

  10. 10.

    Biedler JL, Helson L, Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2643–2652, 1973

  11. 11.

    Buck J, Bruchelt G, Girgert R, Treuner J, Niethammer D: Specific uptake ofm-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 45: 6366–6370, 1985

  12. 12.

    Vaidyanathan G, Zalutsky MR: No-carrier-added synthesis ofmeta-[131I]-iodobenzylguanidine. Appl Radiat Isot 44: 621–628, 1993

  13. 13.

    Zalutsky MR, Garg PK, Friedman HS, Bigner DD: Labeling monoclonal antibodies and F(ab')2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity andin vivo localizing capacity. Proc Natl Acad Sci USA 86: 7149–7153, 1989

  14. 14.

    Vaidyanathan G, Zalutsky MR: 1-(m-[211At]astatoben/yl) guanidine: synthesis via astato demetalation and preliminaryin vitro andin vivo evaluation. Bioconjugate Chem 3: 499–503, 1992

  15. 15.

    Bast RC Jr de Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J: Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer 45: 499–503, 1985

  16. 16.

    Lambrecht RM, Mirzadeh S: Cyclotron isotopes and radiopharmaceuticals — XXXV. Astatine-211. Int J Appl Radiat Isot 36: 443–150, 1985

  17. 17.

    Johnson EA, Byron WB Jr: The Spearman estimator for serial dilution assays. Biometrics 17: 79–88, 1961

  18. 18.

    Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL: Radioimmunotherapy of B-cell lymphoma with [131I]anti-Bl (anti-CD20) antibody. N Engl J Med 329: 459–165, 1993

  19. 19.

    Press OW, Eary JE Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219–1224, 1993

  20. 20.

    Moriuchi S, Shimizu K, Miyao Y, Hayakawa T: Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastoma and gliomas. Br J Cancer 68: 831–837, 1993

  21. 21.

    Feickert HJ, Pietsch T, Hadam MR, Mildenberger H, Riehm H: Monoclonal antibody T-199 directed against human medulloblastoma: characterization of a new antigenic system expressed on neuroectodermal tumors and natural killer cells. Cancer Res 49: 4338–4343, 1989

  22. 22.

    Bourne S, Pemberton L, Moseley R, Lashford LS, Coakham HB, Kemshead JT: Monoclonal antibodies M340 and UJ181.4 recognize antigens associated with primitive neuroectodermal tumours/tissues. Hybridoma 8: 415–126, 1989

  23. 23.

    Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, Slack N, Bullimore J, Pizer B, Papanastassiou V, Kemshead JT, Coakham HB, Lashford LS: Intrathecal administration of131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 62: 637–642, 1990

  24. 24.

    Mairs RJ, Angerson W, Gaze MN, Murray T, Babich JW, Reid R, McSharry C: The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids. Br J Cancer 63: 404–09, 1991

  25. 25.

    Iavarone A, Lasorella A, Servidei T, Riccardi R, Troncone L, Mastrangelo R: Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells. J Nucl Med 35: 186–190, 1991

  26. 26.

    Iavarone A, Lasorella A, Servidei T, Riccardi R, Mastrangelo R: Uptake and storage of M-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 53: 304–309, 1993

  27. 27.

    Lashford LS, Hancock JP, Kemshead JT:Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BC(2C). Int J Cancer 47: 105–109, 1991

  28. 28.

    Montaldo PG, Lanciotti M, Casalaro A, Cornaglia-Ferraris P, Ponzoni M: Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res 51: 4342–4346, 1991

  29. 29.

    Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD: Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 54: 4719–4725, 1994

  30. 30.

    Vaidyanathan G, Strickland KD, Zalutsky MR: Meta[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer 57: 908–913, 1994

  31. 31.

    Larsen RH, Bruland ØS, Hoff P, Alstad J, Lindmo T, Rofstad EK: Inactivation of human osteosarcoma cellsn vitro At-TP-3 monoclonal antibody: comparison with211At labeled bovine serum albumin, free211At, and external beam x-rays. Radiat Res 139: 178–184, 1994

  32. 32.

    Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL: Cellular kinetics dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res 130: 220–226, 1992

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Strickland, D.K., Vaidyanathan, G., Friedman, H.S. et al. Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. J Neuro-Oncol 25, 9–17 (1995). https://doi.org/10.1007/BF01054718

Download citation

Key words

  • medulloblastoma
  • meta-iodobenzylguanidine
  • meta-astatobenzylguanidine
  • radiotherapy